HIV and its effects on bone: a primer for rheumatologists.
Study Goal
The researchers aimed to explore the role of calcium supplementation in preventing bone loss in HIV patients, particularly in relation to antiretroviral therapy (ART).
Results Summary
The study found conflicting evidence on whether calcium and vitamin D supplementation can prevent bone loss associated with specific ART regimens in HIV patients. Increased rates of osteopenia and osteoporosis were observed, but the impact on fracture risk remains unclear.
Population
HIV patients with comorbid bone complications such as osteopenia and osteoporosis.
Effective Dosage
Not specified
Duration
Not specified
Interactions
Possible interaction with antiretroviral therapy (ART) mentioned, but specifics not detailed.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
- | increase | rates of comorbid chronic diseases such as bone complications | patients with HIV | - | increasing | #1 |
- | increase | rates of osteopenia and osteoporosis | the HIV population | - | increased | #2 |
antiretroviral therapy (ART) | increase | increased rates of osteopenia and osteoporosis | the HIV population | - | possibly the effect | #3 |
particular ART regimens | decrease | bone mineral density | the HIV population | - | decrease | #4 |
particular ART regimens | increase | fracture | the HIV population | - | translates into an increased risk | #5 |
supplementation of vitamin D and calcium | decrease | the bone loss seen with specific ART regimens | - | - | can prevent | #6 |
PURPOSE OF REVIEW: As patients with HIV are living longer because of effective treatments, rates of comorbid chronic diseases such as bone complications are increasing. There is a growing body of literature showing increased rates of osteopenia and osteporosis in the HIV population. Less is known about the risk of fracture, as well as other bone complications, such as avascular necrosis (AVN). RECENT FINDINGS: Increased rates of osteopenia and osteoporosis are seen in the HIV population, likely secondary to an interaction of traditional osteoporotic and HIV-specific risk factors, and possibly the effect of antiretroviral therapy (ART). There are conflicting recent data as to whether the decrease in bone mineral density seen in the HIV population, specifically with particular ART regimens, translates into an increased risk of fracture. Conflicting evidence emerges from recent studies exploring whether supplementation of vitamin D and calcium can prevent the bone loss seen with specific ART regimens. SUMMARY: Bone disease is common in the HIV population, and will likely be a medical problem increasingly seen by rheumatologists. The role of ART regimens on bone complications such as fracture and AVN is unclear, and further research in this area as well as possible prevention strategies are needed.